about
Generation and characterization of human insulin-releasing cell lines.TGF-β autocrine pathway and MAPK signaling promote cell invasiveness and in vivo mammary adenocarcinoma tumor progression.The synthetic peptide CIGB-300 modulates CK2-dependent signaling pathways affecting the survival and chemoresistance of non-small cell lung cancer cell linesStat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis.Hypoxia-induced nitric oxide release by luminal cells stimulates proliferation and uPA secretion of myoepithelial cells in a bicellular murine mammary tumor.Involvement of protein kinase C α and δ activities on the induction of the retinoic acid system in mammary cancer cells.The rigid steroid 21-hydroxy-6,19-epoxyprogesterone (21OH-6,19OP) is a dissociated glucocorticoid receptor modulator potentially useful as a novel coadjuvant in breast cancer chemotherapy.Synergism between baltergin metalloproteinase and Ba SPII RP4 PLA2 from Bothrops alternatus venom on skeletal muscle (C2C12) cells.Involvement of PKC delta (PKCδ) in the resistance against different doxorubicin analogs.Glypican-3 reexpression regulates apoptosis in murine adenocarcinoma mammary cells modulating PI3K/Akt and p38MAPK signaling pathways.Glypican-3 regulates migration, adhesion and actin cytoskeleton organization in mammary tumor cells through Wnt signaling modulation.Protein kinase C delta inhibits the production of proteolytic enzymes in murine mammary cells.Regulation of galectin-1 expression by transforming growth factor beta1 in metastatic mammary adenocarcinoma cells: implications for tumor-immune escape.Function and expression of CD44 during spreading, migration, and invasion of murine carcinoma cells.Inhibition of invasion and metastasis by glypican-3 in a syngeneic breast cancer model.Circulating 92-kilodalton matrix metalloproteinase (MMP-9) activity is enhanced in the euglobulin plasma fraction of head and neck squamous cell carcinoma.Prognostic value of Mdm2, p53 and p16 in patients with astrocytomas.The Immune System As a New Possible Cell Target for AFP 464 in a Spontaneous Mammary Cancer Mouse Model.Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.Therapeutic blockade of Foxp3 in experimental breast cancer models.Myoepithelial and luminal breast cancer cells exhibit different responses to all-trans retinoic acid.Soluble factors released by the target organ enhance the urokinase-type plasminogen activator activity of metastatic tumor cellsEffects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor modelImpairment of fibrinolysis during the growth of two murine mammary adenocarcinomasAntimetastatic effect of desmopressin in a mouse mammary tumor modelOverproduction of urokinase-type plasminogen activator is regulated by phospholipase D- and protein kinase C-dependent pathways in murine mammary adenocarcinoma cellsApoptotic cell death in mammary adenocarcinoma cells is prevented by soluble factors present in the target organ of metastasisDownregulation of fibronectin transcription in highly metastatic adenocarcinoma cellsInvolvement of TGF-beta(s)/T(beta)Rs system in tumor progression of murine mammary adenocarcinomasAtypical protein kinase C-zeta modulates clonogenicity, motility, and secretion of proteolytic enzymes in murine mammary cellsOral-specific ablation of Klf4 disrupts epithelial terminal differentiation and increases premalignant lesions and carcinomas upon chemical carcinogenesisLevels of plasmatic fibronectin in mice bearing adenocarcinomas of different metastasizing ability
P50
Q33471759-E02DD8AB-7C4E-4DDF-AF67-6C8F7D1E3592Q37693902-D15C9790-0639-4C5D-928A-FD2922E5101AQ38709045-9274D9C0-0232-4810-9312-D27A6BEA6543Q38849205-C1E938BD-22F5-42BB-AA1E-F3278BC3446DQ38908913-AF11C7CE-F108-4883-B837-D0CA7D0E9928Q38994044-38700559-F516-444F-AECF-1CC2584E33F4Q39003882-B7AB4451-3003-440E-A69B-13DA5A749E5FQ39434553-644DE733-A02A-40CE-8045-3865CC099964Q39698442-D58A95F8-03C2-4F23-B63E-7A3EE87FD531Q39872473-53886CF3-CB30-412C-AD0E-A044217B20C0Q39992986-1FD4CDD6-5399-4426-AFAA-25C38AA392F4Q40102424-BEBCF756-E702-44E5-9824-1BDDA50B7373Q40245081-1B7EC5D6-142E-43D9-836D-873A587F9ACFQ41021122-E44B60B0-45F5-49D9-AA8C-E81B045D0D33Q43872108-5BA90230-8443-4F4F-9C6B-7A8E91B89567Q43937949-6D223EBC-BE24-4468-9FA5-44B9B921869FQ47287484-B852510D-CDFC-4F53-96E0-C5E4D1C07B35Q48229835-DF381D90-F39E-4AAC-9EB2-B54A77BDC05AQ48246344-7AD769F9-BAFF-4363-8BFF-1E0F6CA6EF7CQ48325267-0A572ACF-365E-48BB-B2E5-5F36FDA34456Q52938678-DDD80410-64C5-4CBC-B028-40A0ECD010CFQ70138732-0FDB152F-9DAD-49C2-8A7B-328C60CBB230Q71711015-DC63FBEC-4758-4D9D-8DBC-858B6CAAAFD0Q72885717-E7485C8B-F22F-4097-B59B-18109C38247AQ73316234-D1FBEAFF-CA88-4864-985D-714B2F614288Q73337650-257E1807-63A7-4927-B08D-39C35FF58092Q77397517-9436A991-E52B-4BD0-B86E-617A3309D16FQ77746239-6D3380A4-E78B-4BD0-9424-3B4AE7BEF55CQ79077062-1E69D4F3-DA1D-4486-B7E5-50245358B521Q81012754-5372704C-1552-4E73-97EE-8E1699F510B0Q86566959-DDEFFC38-4144-49D0-B3FC-12253F67B3E9Q93658145-1C8149D0-398B-4BD6-870E-19777F88C095
P50
description
researcher
@en
wetenschapper
@nl
name
E Bal de Kier Joffé
@ast
E Bal de Kier Joffé
@en
E Bal de Kier Joffé
@nl
type
label
E Bal de Kier Joffé
@ast
E Bal de Kier Joffé
@en
E Bal de Kier Joffé
@nl
prefLabel
E Bal de Kier Joffé
@ast
E Bal de Kier Joffé
@en
E Bal de Kier Joffé
@nl
P106
P31
P496
0000-0001-6952-0029